Histrelin
GnRH agonist implant for central precocious puberty and prostate cancer.
What it is
Histrelin (Vantas, Supprelin LA) is a GnRH agonist administered as a subcutaneous implant providing 12 months of continuous release. Vantas is approved for advanced prostate cancer; Supprelin LA is approved for central precocious puberty in children.
Mechanism of action
Same GnRH agonist mechanism as other agents in this class. The 12-month implant duration provides extended suppression with annual replacement procedures.
Approved indications
- Vantas: advanced prostate cancer
- Supprelin LA: central precocious puberty in children
Why this is out of scope at The Tide
Specialty oncology and pediatric endocrinology medication. Implant insertion requires specialty training. Pediatric central precocious puberty is appropriately managed by pediatric endocrinology with appropriate experience.
Where to learn more
Urologic oncology (adult prostate cancer) or pediatric endocrinology (precocious puberty).